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CHAPTER I 
 
Introduction 
 
In this thesis, the power of synthetic chemistry and colloidal nanotechnology will 
be employed for their use in cell therapy and imaging.  A new approach to dendritic cell 
(DC)-based immunotherapy will be examined.  The application of superparamagnetic 
iron oxide (SPIO) nanoparticles as a delivery vehicle will be explored and preliminary 
data of the efficacy of this therapy will be presented, prompting further research in this 
area.  In the last part of the thesis, the development of a near-infrared (NIR) dye for 
amine reactive moieties is described.   
 
Rationale for Thesis 
It is a well-known fact that cancer is still a major health concern in modern times.  
Despite the scientific progress that has been made in treatments for a variety of cancers, 
the Center for Disease Control still reports cancer as the second leading cause of death in 
the United States, surpassed only by heart disease (Murphy, 2012).  Recently, since 1999, 
cancer has eclipsed heart disease as the leading cause of death in Americans under the 
age of 85 (Siegel et al., 2011).  Globally, it is estimated that 7.6 million deaths were 
attributed to cancer in 2008 (Jemal et al., 2011).  Since 1991-1992, cancer death rates 
have failed to meet the extrapolated values expected for mortality rates in the United 
States, accounting for approximately 649,300 cancer deaths in men that have been 
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avoided and 248,600 in women, as of 2007 (Siegel et al., 2011).  Progress has been made 
in treatment of and screening for cancer, but much work is yet to be done.   
The three cancer types which account for the greatest incidence in men in the 
United States are prostate, lung and bronchus, and colon and rectum; among women they 
are breast, lung and bronchus, and colon and rectum (Siegel et al., 2011).  It is apparent 
that epithelial cancers play a large role in the incidence of cancer.  In fact, epithelial 
cancers account for over 85% of all cancers (Backman et al., 2000).  Cancer models 
based in the epithelial tissue are therefore of special importance for preclinical studies of 
cancer treatments.  To that end, a preclinical model of breast cancer is used in our study 
of a new approach to DC-based immunotherapy.   
DC-based immunotherapy is an emerging technique for the treatment of cancer.  
Since the discovery of DC by Ralph Steinman in 1973 (Steinman and Cohn, 1973), 
therapies based on the immune activating powers of this cell type have been developed 
and shown efficacy in both mouse models (Flamand et al., 1994; Grabbe et al., 1991; 
Mayordomo et al., 1995; Porgador et al., 1996) and the clinic (Hsu et al., 1996).  
Immunotherapy has shown limited positive results due to the complicated processes of 
DC preparation and distribution (Martin-Fontecha et al., 2003).  We propose 
improvements to immunotherapy through the use of a nanoparticle delivery vehicle.  
Nanoparticles are preferentially taken up into DCs due to their size (Hirosue et al., 2010).  
Conjugation of immune activating biomolecules to a nanoparticle can, therefore, enhance 
the effectiveness of treatment.  There is a dense population of DCs within the lung tissue 
due to the exposure to the environment (Holt et al., 1993).  This fact has spurred us 
toward the directing immunotherapy agents to the resident DC of the lungs.   
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Background of Immunotherapy 
 
Features and Function of Dendritic Cells 
 The discovery and characterization of DCs by Steinman and Cohn in the early 
1970s brought to the forefront a new area of research for treatment of cancer, 
immunotherapy.  DCs are bone marrow-derived immune cells that are present in small 
numbers and can be isolated from other lymphocytes based on lack of Ig and thy-1 and 
can be practically separated due to the adherent nature of DCs (Steinman and 
Nussenzweig, 1980).  They are professional antigen-presenting cells (APCs) that work to 
process and present antigens on major histocompatibility complex (MHC) molecules for 
recognition by cells of the adaptive immune system, such as T-lymphocytes. DCs have 
multiple roles and dynamically shift phenotypes in response to their environment 
(Grolleau et al., 2005).  The progenitor of DCs is rare in normal blood, just like the DCs 
themselves, accounting for only 0.1% of the cells (Ema, 1990).  Progenitor cells can 
differentiate into both Langerhans cells (from CD1a
+
 DCs) and interstitial DCs (from 
CD1a
-
 DCs), both being CD11c
+
 (Ito et al., 1999).   
Migration of the DCs to the lymph node (LN) is important for the ability of 
peripheral DCs to present antigen to cytotoxic T lymphocytes (CTLs) and T-helper-cells 
(Pham et al., 2009).  Immature DCs reside in tissues that are in contact with the external 
environment, such as the epithelium of the skin, gastrointestinal tract, and respiratory 
tract as well as other peripheral tissues. There, they scan their surroundings for both self 
and foreign antigens and pathogen associated molecular patterns (PAMPs), such as 
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lipopolysaccharide (LPS), acting as a scavenger cell for immune surveillance (Grolleau et 
al., 2005). Upon encountering these “danger” signals, these DCs undergo a differentiation 
and maturation process manifested by the up regulation of key factors needed to induce T 
lymphocyte activation: MHC-I, MHC-II, and costimulatory molecules CD80 and CD86 
important to both the innate and adaptive immune responses. In this manner, DCs are 
capable of presenting tumor antigens and effectively stimulating the immune response, 
targeted against a tumor (Mohty et al., 2002).  
The immature and mature DCs have characteristics specific to each purpose that 
change upon activation.  Immature DCs are characterized by their ability to phagocytosis 
particles and microbes, macropinocytosis to sample extracellular fluid and solutes, and 
adsorptive endocytosis propagating surface receptors (Pham et al., 2009).  When a DC 
uptakes an antigen and matures it loses its ability to uptake antigens, its morphology 
changes to allow high mobility, and increased chemokines are expressed to guide the 
migration to lymphoid tissue (Winzler et al., 1997).   
DCs play a part in innate immunity and adaptive immunity; costimulatory 
molecules and cytokines, such as IL-12 and IL-10, released by the mature DC work to 
mediate innate immune response.  DCs are also involved in the activation of natural killer 
(NK) cells through production of IL-2.  NK cells in turn work to activate DC maturation.  
IL-2 production is also important to the adaptive immune system due to its ability to 
induce proliferation of CD4
+
 and CD8
+
 T-cell and B-cells.  T-helper-cells that have been 
activated by DCs also secrete IL-2 and go on to become either Th1-cells, which secrete 
IFN-γ and activate CTLs, or Th2-cells, which secrete IL-4 and are important to humoral 
immune response through B-cells (Pham et al., 2009).  As can be seen, DCs play a 
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pivotal part in the immune response, both the innate and adaptive arms.  Because of their 
ability to induce and direct a potent immune response, DCs are considered to be 
promising tools for immunotherapy. 
 
Dendritic Cell-Based Immunotherapy 
 The tumor tolerance model in Figure 1 shows the proper activities (anti-tumor 
model) of the DCs are inhibited by growth factors and cytokines in the tumor 
microenvironment, IL-10, VEGF, TGF-β, and IL-6.  These factors prevent DCs from 
differentiating, maturing and migrating.  IL-10 specifically inhibits expression of IL-12 
and costimulatory molecules needed to activate the immune response and induces T-cell 
anergy, a state of immune unresponsiveness.  All these factors, among others, allow the 
tumor to escape the immune response (Pham et al., 2009).   
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Figure 1. Activity of DCs in antitumor immunity and tumor tolerance.  (Pham et al., 2009) 
 
 
 Immunotherapy focuses on this mechanism of tumor tolerance and works to 
circumvent the tumor arsenal by artificially activating the DCs against the tumor.  This is 
most commonly done through ex vivo stimulation of DCs.  DCs are isolated from the 
bone marrow and pulsed with the “danger signal,” a tumor antigen.  The mature DCs are 
then adaptively transferred to the patient through infusion where they are able to migrate 
to the LN and induce uninhibited immune response.   
The efficacy of DC-based therapy for cancer treatment was demonstrated 
successfully with various mouse tumor models (Flamand et al., 1994; Grabbe et al., 1991; 
Mayordomo et al., 1995; Porgador et al., 1996).  This technique was first translated into 
7 
 
clinical therapy for the treatment of follicular B cell lymphoma in 1996 (Hsu et al., 1996).  
In that work, patients received tumor-specific idiotype protein-pulsed DCs via infusion.  
The result of that first clinical trial demonstrated that 8 out of 10 patients developed a 
proliferative cellular response to idiotype protein.  Among those, two patients had partial 
tumor regression.  Encouraged by that study, a large number of DC-based clinical trials 
have been pursued for the treatment of melanoma (Thurner et al., 1999), prostate cancer 
(Fong et al., 2001; Lodge et al., 2000), colorectal cancer (Nair et al., 2002), 
gastrointestinal cancer (Sadanaga et al., 2001), breast cancer (Brossart et al., 2000), and 
renal carcinoma (Holtl et al., 1999; Kugler et al., 2000).  Despite significant 
advancements in DC-based therapy, it has been challenging to develop a simple yet 
robust method for activating the immune system against cancer with antigen-activated 
DCs.  To date, numerous distribution methods have been applied; however, their 
effectiveness has been limited by the complicated processes of DC preparation and 
distribution, and the small percentage of DCs that migrate to the LNs (Martin-Fontecha et 
al., 2003).  
 
Background of Chemical Probes in Imaging 
 Development of chemical probes for imaging is important to cancer research for a 
variety of reasons.  Chemical probes for molecular imaging can be used to study many 
aspects of cancer biology.  The most obvious use of imaging techniques is for detection 
of a disease by image anatomical features of cancer itself.  The use of chemical probes 
allows imaging of not only anatomy, but also visualization of expression and activity of 
specific molecules and biological processes that influence tumor behavior and/or 
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response to therapy (Weissleder, 2006).  Molecular probes may also be used to screen 
preclinical drug discovery, therapeutic assessment and validation of disease biomarkers 
(Nolting et al, 2012).  Molecular imaging can be used to answer the questions of where a 
tumor is located and its size, as well as, tracking the spread to LNs and metastases, and 
information that may warrant altering treatment strategy (Weissleder, 2006).  Computed 
x-ray tomography (CT), magnetic resonance imaging (MRI), ultrasound (US), nuclear 
magnetic resonance (NMR), and optical imaging contribute to the study of cancer as 
traditional anatomical imaging methods as well as for molecular basis of disease (Jaffer 
and Weissleder, 2005).  Use of a magnetic nanoparticle MRI contrast agent has been able 
to detect millimeter sized nodal metastases (Harisinghani et al., 2003).  Resolution of this 
size demonstrates how powerful molecular imaging is for the detection of cancer and 
monitoring growth.  Cancer treatment can be monitored through detection of growth and 
metastases, but also through targeting biological process such as apoptosis and 
angiogenesis.  [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) can 
be used to monitor treatment response through cell growth and death (Weissleder, 2006).  
Drug development can also be impacted by molecular probe imaging through target 
discovery and identifying new efficacy endpoints.  “There is an opportunity to apply 
combinatorial methods, chemical biology, synthetic small molecule compounds, and 
newer nanomaterials as scaffolds to improve pharmacological behavior (Weissleder, 
2006).”  In this thesis two chemical imaging probes will be discussed, the use of SPIO 
nanoparticles and the synthesis of a targeting NIR dye.   
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CHAPTER II  
 
Superparamagnetic Iron Oxide Nanoparticle Probe for Immunotherapy 
 
Rationale 
 Within the realm of immunotherapy, mucin 1 (MUC1) is a highly studied protein 
for use as an immunological target.  Tumor antigens derived from the MUC1 protein are 
one of the most frequently tested in DC-based clinical trials (Kobukai et al., 2011).  The 
NCI Translational Research Working Group has prioritized MUC1 as second among 75 
tumor-associated antigens in regards to therapeutic function, immunogenicity, role of Ag 
in oncogenicity, specificity, expression level, stem cell expression, percentage of patients 
with antigen positive cancer, and cellular location (Cheever et al., 2009).  The MUC1 
tumor antigen is, therefore, ideal for the testing of a novel delivery system.   
 MUC1 is a transmembrane protein specific to epithelial tissue; the heterodimer 
from the mucin family of molecules containing a solely extracellular subunit and a 
subunit containing a short extracellular stem, a single transmembrane domain, and the 
cytoplasmic tail (Hattrup and Gendler, 2006).  The extracellular component is composed 
of a variable number of nearly perfect 20 amino acid tandem repeats (TRs) surrounded by 
five proximal and two distal imperfect repeats.  Serine and threonine residues along these 
repeats provide sites where the protein can be O-link glycosylated to GalNAc (Kinlough 
et al., 2011).  The sequence of the TRs is PDTRPAPGSTAPPAHGVTSA (Vlad et al., 
2004).  MUC1 differs between normal and cancerous cells both in glycosylation of the 
TRs and location.  Specifically in cancerous tissue the protein is underglycosylated.  
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Differences can also be seen in the sites of glycosylation and in the O-glycan structure 
(Taylor-Papadimitriou et al., 1999) with shorter and fewer oligosaccharides.  In normal 
epithelial cells MUC1 is expressed on the apical surface of the ducts and glands, but is 
overexpressed throughout cells in the tumor mass (Mukherjee et al., 2003).   
 The MUC1 protein is overexpressed in many epithelial cancer types.  In addition, 
the protein is aberrantly glycosylated in 90% of human breast cancers (Pinkhasov et al., 
2011), 90% of pancreatic tumors (Dwyer et al., 2006), and >70% of human colon cancer 
(Mukherjee et al., 2007), as well as high levels in lung, prostate, stomach, and ovary 
tumors (Mukherjee et al., 2003).  Presence of overexpressed MUC1 has been correlated 
to aggressive cancer phenotypes and an advantage over normal MUC1 expressing cell 
types (Dwyer et al., 2006). Cancers which have increased expression of MUC1 are more 
resilient to cytotoxic and oxidative agents (Hattrup and Gendler, 2006).   
 MUC1 antigens have been studied in preclinical and clinical trials for DC-based 
immunotherapy to treat multiple epithelial cancers.  Differences can be seen in the 
techniques used to place MUC1 antigen in the DCs as well as in the type of cancer tissue 
treated.  A murine preclinical study tested the ability of DCs transfected with MUC1 
RNA, to express MUC1 Ag, costimulatory, and adhesion molecules, to mount an 
immunological response against MC38 adenocarcinoma cells stably transfected with 
MUC1 cDNA.  MUC1 was expressed in the LNs of the immunized mice as compared to 
the control treated with nontransfected DC.  Humoral and CTL response was seen and 
vaccination of mice was able to prevent the growth of MC38/MUC1 tumors (Koido et al., 
2000).  A clinical study looked at the ability of DCs pulsed with two 9-mer MUC1 
peptides to treat metastatic breast or ovarian cancer.  Of the four MUC1 treated patients, 
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one had regression of multiple subcutaneous lesions after production of CD8
+
 and CD4
+
 
T cells.  Two other patient’s disease was stabilized by the immunotherapy (Brossart et al., 
2000).  In another study, four out of 10 patients treated saw an immunological response, 
as indicated by an increase in CD8
+
 T cells, although only one patient saw a stabilization 
of tumor growth (Pecher et al., 2002).  Immunological and clinical response has been 
seen in advanced metastatic breast and ovarian cancers when treated with MUC1 epitope 
pulsed DCs (Wierecky et al., 2006).  Twenty patients with unresectable or recurrent 
pancreatic cancer were treated with DCs pulsed with a 100-mer peptide from the TR 
domain.  Intradermal injections of the MUC1-DCs were given concurrently with 
intravenous injections of MUC1-CTLs, CTLs stimulated by a MUC1-expressing human 
pancreatic cancer cell line, YPK-1, to improve a previous study done with MUC1-CTLs 
alone.  Five of the 20 patients had a stabilization of disease while one had a complete 
response (Kondo et al., 2008).  Metastatic breast, pancreatic and papillary cancer has 
been treated in clinical trials with DCs transfected with plasmid pCMV MUC1 (cDNA of 
22 repeats of the mucin TR).  Our lab has chosen to focus on the treatment of a mammary 
epithelial tumor cell line C57MG which has been transfected with MUC1 with a 30-mer 
antigen from the TR portion of the protein.   
 Previous work in our lab (Kobukai et al., 2011) has studied DC-based therapy 
with the use of MUC1 antigen.  The use of a delivery molecule, myristoylated 
polyarginine 11-mer peptide (MPA11P), in antigen uptake was analyzed.  A previous 
study (Pham et al., 2007) determined the need for a MPA11P for in vitro uptake of a 
fluorescence probe to DCs.  The 30-mer antigen 
(APDTRPAPGSTAPPAHGVTSAPDTRPAPGS) and the same antigen covalently 
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bonded to the MPA11P (MPA11P(C14-(R)11)-
APDTRPAPGSTAPPAHGVTSAPDTRPAPGS) were compared in their ability to induce 
CD8
+
 T cells and inhibit tumor growth.  DCs were isolated from the bone marrow of 
C57BL/6 mice for use in the in vitro studies.  Three groups of DCs were formed, the first 
were not pulsed with any antigen, the second group was pulsed with MUC1 peptide, and 
the third which was pulsed with MUC1-MPA11P.  The DCs were injected subcutaneously 
in the footpads of C57MG.MUC1 tumor-bearing mice 8 to 10 days post inoculation when 
the tumors had reached approximately 0.4 cm.  A boost was given subcutaneously 10 
days after the first injection.  Both MUC1 and MUC1-MPA11P pulsed DCs induced CD8
+
 
T cell proliferation at 5 days after DC injection, determined by flow cytometric analysis.  
The tumor burden was measured using high-resolution US.  As can be seen in Figure 2 
antigen-pulsed DCs inhibit the growth of the C57MG-MUC1 tumors.  Addition of the 
MPA11P delivery molecule inhibits tumor growth to a greater degree than the MUC1 
alone.   
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Figure 2. The tumor growth was monitored, measured, and compared with the original size (day 0) using 
high-resolution US.  Each point represents a mean of six measurements.  A modest reduced tumor growth 
was observed with MUC1-stimulated DCs (DC + MUC1), and there was a significant difference in the 
groups of mice treated with DC + MUC1-MPA11P compared with those treated with DC + MUC1. *P < .05 
(DC + MUC1-MPA11P vs. DC + MUC1). (Kobukai et al., 2011) 
 
 
 The addition of a delivery vehicle increases the effectiveness of the 
immunotherapy, indicating that increased uptake of the antigen can be mediated by 
conjugation to a molecule that is readily endocytosed.  Along with delivery molecules 
such as MPA11P, nanoparticles are known to taken up by DCs (Hirosue et al., 2010).  
Conjugation of antigen to nanoparticles have the potential to be delivered increasingly 
well into DC and induce an immune response.  Nanoparticles have the added advantage 
over MPA11P type delivery molecules of multivalency.  Nanoparticles have the ability to 
conjugate to a variety of biomolecules, allowing for versatility in design as a delivery 
molecule.   
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Methods and Results 
 
Delivery Molecule Design 
 Design of an ideal carrier molecule takes into consideration a variety of 
characteristics.  The size of the molecule is important; nanoparticles are molecules that 
have a particularly desirable size to be taken up by DCs. Specifically nanoparticles that 
are smaller than 45 nm in diameter have been shown to target resident DCs within the 
LNs and when coupled with a protein were able to induce humoral and antigen-specific 
CD8
+
 T cell responses (Hirosue et al., 2010).  Biocompatibility is also important, a 
molecule must be nontoxic and able to be processed and flushed out of the body without 
any harmful byproducts.  The third important characteristic is the ability of the molecule 
to be conjugated to the antigenic peptide, preferably the ability to conjugate a variety of 
molecules.   
 
Superparamagnetic iron oxide nanoparticles 
The SPIO nanoparticles are useful as a delivery vehicle due to the multivalency, 
biocompatibility, as well as the added ability to track the particles through MRI.  
Dextran-coated iron oxide nanoparticles produced in our lab are found to have a mean 
diameter of approximately 30 nm (Figure 3), within the ideal size for a delivery 
molecule.  The dextran surface can be modified using an epoxy amine linker to produce 
an easily conjugated amine surface.  Since SPIO nanoparticles have been used as a 
contrast agent for MRI the toxicity of the nanoparticle has been studied in both mice and 
humans.  In mice, SPIO nanoparticles are not known to cause toxicity. SPIO 
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nanoparticles are seen to distribute to the heart, spleen, liver, lung, kidney, and brain then 
eliminated quickly without pathology.  In both single and repeated dosing little 
nanoparticle buildup is seen (Liu, 2008).  In humans, acute toxicity of SPIO nanoparticles 
have been found to be comparable to clinically approved infused intravenous contrast 
agents and there is no evidence that use of SPIO nanoparticles as a contrast agent causes 
kidney damage (Winer et al., 2011).   
DCs have been shown to be able to uptake iron oxide nanoparticles.  Previous 
work in our lab (Kobukai et al., 2010) used polylysine as a transfecting reagent to 
mediate the uptake into DCs, although a study by de Vries et al. showed that SPIO 
nanoparticles can be taken up without the need of a delivery agent, requiring a longer 
incubation time (de Vries et al., 2005).  The longitudinal and transverse relaxation rates 
(R1 and R2, respectively) of SPIO nanoparticles can be seen in Figure 3.  The R2/R1 ratio 
is high making them suitable for T2-weighted imaging.   
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Figure 3. Physical properties of the synthesized dextran-coated SPIO particles. a: TEM image of the SPIO 
nanoparticles. b: The distribution of the iron core calculated from the TEM image. c: The overall size of 
dextran-coated SPIO particles measured by a Zetasizer. d: The R values. (Kobukai et al., 2010) 
 
 
The SPIO nanoparticles consisting of an iron oxide core and dextran coating were 
produced from The Pham Laboratory (Kobukai et al., 2010). A saturated mixture of 
dextran and ferric chloride was coalesced with a ferrous chloride solution at room 
temperature. The pH was elevated to 10 via drop wise addition of an ammonium 
hydroxide solution. The resulting solution was stirred for several hours. Using deionized 
water, synthesized particles were separated from the starting materials and dialyzed into a 
buffer containing normal physiologic concentrations of sodium citrate and sodium 
chloride.  
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Epoxy amine linker 
As mentioned previously the hydroxyl surface of the dextran-coated SPIO 
nanoparticles must be modified due to the poor nucleophilicity of the surface alcohols.  
To this end, a linker was developed by our lab consisting of an epoxide terminus and an 
amine terminus.  The short five carbon linker’s epoxide terminus is able to react easily 
with the alcohol groups on the surface of the dextran coated nanoparticle.  The amine 
terminus of the linker is then presented on the surface of the nanoparticle.   
Synthesis followed the scheme shown in Figure 4 and published by Nickels et al 
(Nickels et al., 2010).  The intermediate 5, Pent-4-en-1-aminium 4-
methylbenzenesulfonate was developed from our group, it was produced from 5-
bromopent-1-ene through a Gabriel synthesis followed by protection of the terminal 
amine group as an alkenylammonium salt.  The alkenylammonium salt prevents the 
oxidizing of the amine in the next step as well as by nucleophilic attack of the amine on 
the epoxide ring.   
A dimethyldioxirane solution of was made fresh as follows: acetone (39.0 mL, 
531 mmol), sodium bicarbonate (36.0 g, 429 mmol), and water (60 mL) were added to a 
500 mL three-neck round bottom flask, which was fitted with a solid addition funnel, 
nitrogen inlet and Vigreux column.  Attached to the Vigreux column was a 100 mL two-
neck round bottom flask equipped with a dry-ice condenser, which as then attached to a 
house vacuum line equipped with an inline vacuum trap.  Nitrogen was used to purge the 
entire system.  Oxone® (75.8 g, 123 mmol) was added slowly to the reaction mixture via 
the solid addition funnel over a period of 1.5 hours with constant stirring and a steady 
flow of nitrogen.  After addition of Oxone® the entire system was put under the house 
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vacuum for a period of 2 hours.  Dimethyldioxirane in acetone (23 mL, 0.099 M) was 
trapped in the two-neck round bottom flask, which was subsequently sealed and stored in 
a freezer until needed. 
To a dry 100 mL round bottom flask were added pent-4-en-1-aminium 4-
methylbenzenesulfonate (0.352g, 1.37 mmol) and dry CH2Cl2 (10.0 mL), which was then 
cooled to 0 °C under an atmosphere of nitrogen.  The freshly prepared dimethyldioxirane 
solution (23.0 mL, 2.28 mmol) was added slowly, and the resultant clear reaction mixture 
was stirred at 0 °C for a period of 1.5 hours, then at 4 °C overnight.  The solution was 
added to dry diethyl ether (150 mL), which produced a white precipitant.  The precipitate 
was filtered and rinsed with additional cold diethyl ether then dried under high vacuum 
producing the final product, the epoxy amine linker (8) as a white solid (0.334 g, 89.4% 
yield).   
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Figure 4. Design and syntheses of epoxy amine linker for functionalizing nanoparticles (Adapted from The 
Pham Laboratory). 
 
 
The product was verified by 
1
H NMR in CDCl3 using a Bruker 300 MHz and 
peaks were assigned based on the epoxy amine linker (Figure 5).   
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Figure 5. 
1
H NMR of epoxy amine linker product. 
 
 
Coating the nanoparticle with an epoxy amine linker 
The epoxy amine linker was coupled to the SPIO nanoparticle as seen in Figure 
6.  The nanoparticles were prepared as described above and resuspended in phosphate 
buffered saline (PBS) at 11 mg/mL of iron. The epoxy amine linker (35.4 mg, 129 mmol) 
was dissolved in the nanoparticle solution (2mL, 22 mg), producing a solution with 
approximately 500 times excess epoxy amine linkers (the number of molecules vs. 
particles).  The reaction was performed overnight, at room temperature, with gentle 
stirring.  Excess free epoxy amine linker was removed from the nanoparticles using PD-
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10 desalting column (GE Healthcare, Pittsburgh, PA) following the manufacturer’s 
recommended procedure. 
 
 
 
Figure 6.  Functionalization of dextran-coated iron oxide nanoparticles with an epoxy amine linker 
resulting in approximately 40–60 amines on the surface measured with fluorescamine. (adapted from Pham 
Laboratory) 
 
 
Use of N-succinimidyl 3-(2-pyridyldithio) propionate linker 
 The amine surface of the SPIO nanoparticle allows for easy conjugation of a 
biomolecule through a crosslinker.  The design of conjugation takes into account the need 
for release of the biomolecules once inside the DCs.  The reductive environment of 
trafficking within the cell can be exploited by inclusion of a reduction-sensitive 
conjugation, such as a disulfide bond.  Use of reducible conjugation has enhanced 
efficacy in intracellular targeting of biomolecules with a synthetic carrier (Hirosue et al.; 
van der Vlies et al., 2010).  N-succinimidyl 2-(2-pyridyldithio) propionate (SPDP) is a 
short-chain crosslinker containing a disulfide bond.  The heterobifunctional reagent has 
an N-hydroxysuccinimide (NHS) ester terminus and a 2-pyridyl disulfide terminus.  The 
NHS-ester reacts easily with amine groups; the 2-pyridyl disulfide reacts with thiols 
(Carlsson et al., 1978), found in peptides containing cysteine.  SPDP is a commercially 
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available linker through Thermo Scientific as described in Carlsson et al (Carlsson et al., 
1978).   
Conjugation with SPDP was done following the procedure in the reagent 
instructions and indicated in Figure 7.  A 20 mM solution of SPDP reagent was formed 
by dissolving 2 mg of SPDP in 320 μL of dimethyl sulfoxide (DMSO).  Amine 
containing nanoparticle (5mg) was dissolved in PBS (1.0 mL) to which was added 25 μL 
of the 20 mM SPDP solution.  After the reaction was left at room temperature for 30 
minute nonreacted SPDP was removed with an equilibrated disposable PD-10 desalting 
column (GE Healthcare, Pittsburgh, PA).  The column had been equilibrated according to 
manufacturer’s instructions with 25 mL of PBS.  Sulfhydryl containing biomolecule (3 
mg) was added to the collected solution and incubated overnight at room temperature.  
The reaction was confirmed by UV-vis Spectrophotometer (Agilent Technologies, Santa 
Clara, CA) showing a peak at 343 nm (the absorbance of the Pyridine 2-thione 
byproduct).   
 
 
 
Figure 7. Reaction scheme for conjugation of amine and thiol containing biomolecules.  
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Bioconjugation of SPIO Nanoparticle  
 
α-GalCer as adjuvant 
 As immunotherapy has become more studied it has become apparent that 
activating the immune system with antigen alone is not very efficient.  A successful 
cancer vaccine should work in multiple ways to activate the immune system, especially 
simultaneous activation of both the innate and adaptive arms of the immune system 
(Lakshminarayanan et al.).  Inclusion of an innate immune adjuvant is a technique used to 
enhance efficacy of therapy (Mukherjee et al., 2007).  α-Galactosylceramides (α-GalCer) 
are a family of immunostimulants developed form a natural product of an Okinawan 
marine sponge (Franck and Tsuji, 2006).  The natural product, as well as, the synthetic 
material, KRN7000, activates immunity through natural killer T (NKT) cells.  NKT cells 
are innate lymphocytes that have phenotypic and functional properties of both NK cells 
and T cells (Franck and Tsuji, 2006).  After endocytosis by APCs, α-GalCer is presented 
on the cell surface by CD1d gene family to NKT cells (Morita et al., 1995; Zhou et al., 
2002).   Activated NKT cells give a boost to the innate and adaptive immune cells: NK 
cells, macrophages, DCs, CD4
+
 and CD8
+
 T cells, both through release of cytokines and 
direct cell-to-cell contact (Thapa et al., 2009).  Thereby, α-GalCer can increase the 
efficiency of DC-based therapy.  The adjuvant family is varied by fatty acid chain 
modifications, many variations have been found to be active (Franck and Tsuji, 2006).  
Soluble α-GalCer successfully inhibits primary tumor formation in multiple murine 
sarcoma and carcinoma lines (Hayakawa et al., 2003).  Clinical trials indicate that α-
GalCer pulsed DCs are able to activate NKT cells against cancer in humans, albeit to a 
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lesser degree than in murine models.  This therapy significantly increased antigen 
specific, interferon (IFN)-γ-producing, and memory T cells when given prior to an 
inactivated influenza vaccine in one patient (Chang et al., 2005).  Injection of soluble α-
GalCer has been demonstrated to cause anergy of the NKT cells, an intrinsically 
functional inactivation due to strong T-cell receptor signals delivered in the absence of 
costimulation.  This can be avoided by loading mature DCs with α-GalCer in vitro 
(Sullivan and Kronenberg, 2005) or by conjugating the adjuvant to a nanoparticle (Thapa 
et al., 2009).  A study by Reddy et al. showed that by conjugating an adjuvant to a 
nanoparticle it is possible to activate an immune response without pulsing DCs ex vivo 
(Reddy et al., 2007).  The α-GalCer used for our studies, seen in Figure 8, is modeled 
from KRN7000, with modification to the fatty acid chain, shortened by two methyl 
groups, and the hydroxymethyl group, providing an accessible thiol.   
 
 
 
Figure 8. Structure of thiolated α-GalCer. 
 
 
 Conjugation of α-GalCer to aminated SPIO nanoparticle using the SPDP 
crosslinker proceeded as previously described and shown in Figure 7.  Due to relatively 
poor solubility in organic and aqueous solvents, glycolipids are often dissolved in DMSO 
and then diluted in the solvent of choice (Liu et al., 2006).  The thiolated α-GalCer was 
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provided in a 1 mg/mL solution of DMSO.  Working as the sulfhydryl containing 
biomolecule, 100 μL of the α-GalCer solution were added to the pyridyldithiol-activated 
SPIO nanoparticles.  The product was monitored by analyzing its absorbance at 343 nm 
on the UV-vis Spectrophotometer (Agilent Technologies, Santa Clara, CA).   
 
 
 
Figure 9. Scheme of conjugation of thiol modified α-GalCer to aminated SPIO nanoparticles.  The amino 
groups on the surface of SPIO nanoparticles (A) were allowed to react with a SPDP crosslinker.  The 
pyridyldithiol-activated SPIO nanoparticles (B) was left in the presence of thiolated α-GalCer to produce a 
SPIO-α-GalCer conjugate (C) (adapted from Pham Laboratory). 
 
 
 To test the efficacy of the α-GalCer conjugated SPIO nanoparticles, an 
experiment was done in vivo comparing the immune response to that of soluble α-GalCer.  
Wild-type C57BL/6 mice were injected subcutaneously with varying concentrations of 
either α-GalCer conjugated to SPIO nanoparticles, soluble α-GalCer, or SPIO 
nanoparticle alone.  After 4 hours blood was collected and the sera isolated and analyzed 
for IL-4 concentration using an ELISA.  The cytokine production is reported in Figure 
10.  
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Figure 10. IL-4 production as a measure of immune response after injection of adjuvant laden 
nanoparticles, nanoparticles alone and adjuvant alone.  Conjugation of the adjuvant to the nanoparticle 
increases activation of the immune response at 1 ng/mL concentration. 
 
 
α-GalCer does not lose its efficacy for inducing an immune response when 
conjugated to a nanoparticle.  Comparable IL-4 activation can be seen within a 0.1 to 100 
ng/mL concentration with a particular advantage to the nanoparticle conjugated adjuvant 
around 1 ng/mL concentration of α-GalCer.   
 
Synthesis of MUC1, α-GalCer conjugated SPIO nanoparticles 
The SPIO nanoparticles provide an opportunity to present multiple molecules as 
antigens to the immune system simultaneously.  In this direction, we propose the 
development of a particle which is bound to both tumor antigen and the glycolipid 
molecule α-GalCer.  Conjugation of the nanovaccine was accomplished with two 
reactions of the SPDP crosslinker following the scheme in Figure 11.  First the 31-mer 
MUC-1 peptide (APDTRPAPGSTAPPAHGVTSC) was conjugated, followed by 
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conjugation of the thiolated α-GalCer (1mg/mL in 10% methanol (MeOH) in 
tetrahydrofuran (THF)).   
 
 
 
Figure 11. Scheme for conjugation of the MUC1 antigen and α-GalCer glycolipid to SPIO nanoparticles.  
The amino groups on the surface of SPIO nanoparticles (A) were allowed to react with a SPDP crosslinker.  
The pyridyldithiol-activated SPIO nanoparticles (B) was left in the presence of cysteine containing MUC1 
to produce a SPIO-MUC1 conjugate (C).  Similarly the conjugate was again reacted with SPDP to produce 
more activated linkers on the surface of the nanoparticle (D) which bound to the thiol containing α-GalCer 
to form a SPIO-MUC1,α-GalCer nanovaccine (E) (adapted from Pham Laboratory). 
 
 
The absorbance of the solution was measured prior to and follow the addition of 
α-GalCer or MUC1.  The release of pyridine-2-thione could be monitored by the 
absorbance at 343 nm and the quantity of conjugated molecules could be calculated using 
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Beer’s law, A = εbc, where A is the absorbance, ε is the molar extinction coefficient 
(8.08 x 103 M-1cm-1 for pyridine-2-thione), b is the path length of the sample (1 cm), 
and c is the concentration.  For MUC1 conjugation the average change of absorbance was 
0.1282 AU indicating that 3 x 10
-8
 moles of pyridine-2-thione was released and replaced 
by MUC1, 2.6 % of the MUC1 added to the solution.  In the case of α-GalCer the average 
change of absorbance was 0.0187 AU indicating that 1 x 10
-7
 moles of α-GalCer had 
replaced pyridine-2-thione, 8.7% of the α-GalCer that was added to solution.   
 
Treatment of C57MG.MUC1 tumors 
 A preliminary study was done in a murine model of a MUC1 cancer to ascertain 
the in vivo activity of our nanovaccine.  To test the nanovaccine, adult MUC1 transgenic 
mice were implanted with MUC1-transfected C57MG tumors. The tumor antigen- and 
adjuvant-conjugated nanoparticle was delivered to the mice via subcutaneous injection. 
Tumor growth in the treated and untreated groups of mice was measured by US over a 5-
week period. 
One million C57MG.MUC1 cells in 200 μL serum-free Dulbecco modified Eagle 
medium were injected subcutaneously into the left mammary fat pad of MUC1 transgenic 
(MUC1.Tg) mice which were available in our colonies (n = 5).  Seven days after 
inoculation tumors were measured with a caliper to be approximately 0.4 cm and the 
therapy began (day 0).  Three mice (treatment) were immunized with 20 μL of 
approximately 2 mg/mL SPIO-(MUC1, α-GalCer) in PBS by subcutaneous injection into 
the footpads three times per week.  Tumor size in both the treatment and control group 
was measured twice weekly with a caliper along the largest diameter of the tumor (every 
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third measurement is reported in Figure 12).  None of the tumors reached 10% of the 
body weight during our 5-week study.   
 
 
 
Figure 12. The tumor growth was monitored, measured, and compared with the original size (day 0) using a 
caliper.  Each treatment point is the average of three mice, each control point is the average of two mice.  
Error bars show one standard deviation. 
 
 
Tumor growth in the MUC-1 treated mice was inhibited as compared to the non-
treated group.  In order to analyze further the treatment using the nanovaccine, cytokines 
produced during immune responses were measured.  Injection of the nanovaccine is 
expected to induce an immune response as it’s mechanism of tumor growth inhibition.  
The cytokine production was measure with an ELISA for INF-γ of the mouse serum.  6 
hours after the first treatment, blood was collected from each mouse.  The serum was 
isolated by centrifuge.  A sandwich ELISA assay was done of the sera using Rat α-mouse 
IFN-γ antibodies detected by avidin peroxidase and visualized with TMB substrate 
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according to BD Biosciences protocols.  The concentrations calculated from the standard 
curve are shown in Figure 13.   
 
 
 
Figure 13. IFN-γ concentration measured in the serum of treated and untreated mice. 
 
 
 The concentration seen in both the treated and untreated mice were negligible 
compared to the standard curve concentrations (30-1000 pg/mL).  This indicated that the 
injected nanoparticles did not produce a IFN-γ detectable immune response 6h post 
injection.  In order to confirm this, an experiment was done to compare the 
immunological response to the nanovaccine as compared to a complete solution 
containing microbial peptides and soluble α-GalCer.  Eight wild-type C57BL/6 mice 
were used for this study in four groups.  Each mouse was injected intraperitoneal with 
100 μL of solution based on groups.  The first group, two mice, received 0.5 mg/mL 
SPIO nanoparticles conjugated to MUC1 peptide and α-GalCer lyposaccaride (SPIO-
(MUC1, α-GalCer)).  The second group received 0.5 mg/mL SPIO nanoparticles 
conjugated to α-GalCer (SPIO-(α-GalCer)).  The third group was injected with a solution 
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containing MUC1 peptide (50 μg), two microbial peptides (70 μg) and α-GalCer (1 μg) 
(Complete).  The final group was injected with two microbial peptides (70 μg) and α-
GalCer (1 μg) (Mock).  After 6 hours, blood was collected from each mouse.  The serum 
was isolated with centrifuge and an ELISA was done for IFN-γ as described above.  Data 
is reported in Figure 14. 
 
 
 
Figure 14. IFN-γ concentration measurements for each mouse are shown categorized by group. 
 
 
It can clearly be seen that the synthesized nanovaccine did not activate an immune 
response as was expected.  The positive control of soluble antigen and adjuvant with 
microbial peptides indicates that these molecules are capable of activating an IFN-γ 
producing immune response.  Results of SPIO-(α-GalCer) from this study do not agree 
with the earlier study of nanoparticle concentration. A few caveats need to be examined. 
This in vivo analysis of cytokines may indicate that there were inconsistencies with the 
synthesis or conjugation of the ligands onto the SPIO nanoparticles. Particularly, 
amination of the nanoparticles with the epoxy amine linker is complicated, and thus 
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process requires skillful maneuvers. And if this foundation is not achieved reproducibly it 
may affect in our attempt to conjugate antigens and adjuvants.  It is also noteworthy that 
this data represents the outcome obtained from experiments using a single set of 
nanovaccine compounds; more experiments need to be achieved with modifications in 
order to improve the therapy. For example, analytical techniques need to be performed to 
ensure antigens and other ligands are attached on the SPIO nanoparticles. Additionally, 
precise concentration of the antigen and adjuvant need to be taken in account and 
calibrated against the controls for in vivo therapy. 
 
Alternative Approach to Aminated SPIO Nanoparticle Synthesis 
 In an attempt to improve the synthesis, an alternative approach for developing 
aminated SPIO nanoparticles was employed, modifying dextran.  Dextran is a white solid 
and the presence of an amino group can quickly be characterized through ninhydrin 
staining by purple product formed (the brown color of SPIO nanoparticles prevents this 
test from being used to characterize the aminated product).  A two-step synthesis was 
carried out following the procedure outlined in Rebizak et al and shown in Figure 15 
(Rebizak et al., 1997).   
 Step one synthesis of carboxymethyldextran (CMD) was done as follows: dextran 
10 (GE Healthcare) (10.0 g, 52.0 mmol glucose units) and 6 N NaOH (82.5 mL) at room 
temperature were added to a 250 mL round bottom flask.  Solution was stirred until 
dextran was dissolved.  Chloroacetic acid (20.5 g, 217 mmol) was added to the solution.  
The mixture was stirred at 60 °C for 50 minutes then cooled to room temperature.  The 
solution was then added to MeOH (500 mL) to producing a white precipitate.  The 
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precipitate was filtered and washed with MeOH then dried under high vacuum producing 
a white solid, CMD (9.119 g, 65.7% yield). 
 The second step proceeded as follows: To a 250 mL round bottom flask 
containing 100 mL of H2O was added CMD (10.0 g, 36.7 mmol glucose units).  The 
solution was stirred until the solid had dissolved then the pH was adjusted to 3 using 1N 
HCl.  A 2-Ethoxy-1-(ethoxycarbonyl)-1,2-dihydroquinoline (EEDQ) solution was 
prepared as follows: EEDQ (15.4 g, 62 mmol) was added to a 250 mL round bottom flask 
containing MeOH (233mL).  The EEDQ solution was added drop wise to the CMD 
solution with stirring to avoid formation of a precipitate.  Ethylenediamine (20.7 mL, 310 
mmol) was added to the solution and left at room temperature for 4 hours.  The solution 
was then added to MeOH (500 mL) producing a white precipitate.  The precipitate was 
filtered and washed with MeOH then dried under high vacuum producing a white solid, 
aminated carboxymethyldextran (CMDA) (7.840 g, 73.3% yield).   
 
 
 
Figure 15. Scheme of CMDA synthesis.  Dextran (A) is converted to a carboxylic acid in CMD (B) and 
further conjugated to an amine terminus in CMDA (C). 
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A portion of the CMDA product, CMD, and dextran were dissolved in water and 
spotted on a TLC plate.  After drying, ninhydrin (2,2-Dihydroxyindane-1,3-dione) 
solution was added and the plate was heated on a hot plate at 80 °C for approximately 5 
minutes.  The CMDA spot appeared purple, while the CMD and dextran spots did not 
color.  Although ninhydrin test of the product were positive for the amino group, 
1
H 
NMR of the polymer did not show consistent results (data not shown).  
13
C NMR was 
also unable to verify the synthesis of the CMDA product.  Final characterization was 
done with Fourier transfer-Infrared (FT-IR) spectroscopy to show the appearance of an 
amine peak as compared to the Dextran.  All samples were prepared by placing 20 μL of 
solution (50mg/ml) on Germanium Attenuated Total Reflection (Ge ATR) crystal to form 
a film (~ 1 cm diameter).   
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Figure 16. FT-IR of Dextran (a) versus the CMDA product (b).  A new amino group would show a peak 
around 1650 cm
-1
. 
 
 
 The FT-IR was expected to show a deep increase in the peak near 1650 cm
-1
.  As 
can be seen in Figure 16 only a negligible difference can be seen between the CMDA 
product and dextran starting material around 1650 cm
-1
.  The negative results seen here 
were supported by failure to achieve coating of SPIO nanoparticles comparably to 
dextran.   
 
Future Work 
 Further work is being done in this area to improve synthesis of the nanoparticle.  
Alternate synthesis of an aminated coating material is being developed.  With 
improvement of the aminated nanoparticle the conjugation to MUC1 peptide and α-
GalCer can be analyzed and adjustments made to optimize the number of biomolecules 
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on the surface of the nanovaccine.  Combination of antigen and adjuvant to the surface of 
the nanoparticle is expected to induce a powerful immune response.  To verify this, 
studies can be done in vitro to assess production of cytokines when pulsed to immature 
DCs.  Movement into in vivo studies will analyze the immune response to the 
nanovaccine as previously described through concentration measurements of cytokines 
such as IL-4 and IFN-γ, including analysis of the mechanism of immune activation.  
These measurements can be done with a variety of injections routes to find the optimal 
means of creating an immune response.  Although inconclusive, preliminary data of a 
positive tumor response to the nanovaccine is observed. Tumor response studies in 
murine models should be repeated to verify this finding and optimize treatment.  
Treatment with the nanovaccine alone should be compared to treatment with nanovaccine 
pulsed DCs to verify that the nanovaccine alone is able to activate immune response 
comparable to the standard procedure at this time.   
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CHAPTER III 
 
Nebulization 
 
Rationale 
 Immunotherapy has been developed from varied angels of attack, which has led to 
inconsistencies between research groups in the best means of attaining an immune 
response.  One area in which this is apparent is the route of delivery.  Attention has be 
drawn to the fact that no consensus has been reached on the best way to reintroduce 
pulsed DCs into the patient (Pham et al., 2009).  This step is of importance due to the 
requirement that the mature DCs are able to migrate to the LN and present the antigen to 
the T cells.  A study done as late as 2011 (Bouvier et al., 2011) continued to examine the 
route of delivery, directly testing two of the possible routes against each other, 
intradermal and intravenous injection.  Each route was found to have advantages over the 
other and again a consensus could not be reached as to the best route of delivery across 
the board.  
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Figure 17. CD11c staining in lung tissue shows the presence of DCs. 
 
 
 The development of a nanoparticle delivery system containing antigen and 
adjuvant molecules allows for the possibility of DC uptake of the nanovaccine in vivo.  In 
this case the route of delivery must be analyzed separately from the traditional 
immunotherapy approach.  Areas rich in endogenous DCs are optimal for delivery of the 
nanovaccine allowing for the greatest chance of DC uptake.  DCs are widely distributed 
in the body, although they comprise only a small proportion (0.1-1%) of the cells in 
different lymphoid and non-lymphoid tissues (Ema, 1990).  Sertl et al studied histology 
of the lung to determine that the epithelial cells contained 1% DCs, which were found to 
be powerful APCs.  The DCs were the only MHC class II antigen-positive cells found in 
the tracheobronchial epithelium.  They were present in the epithelial cells extending 
toward the lumina, in the vascular walls, and were found peripherally as far as the 
alveolar septa and the visceral pleura (Sertl et al., 1986).  Lung tissue contains some of 
the highest concentration of DCs because DCs on the epithelial surfaces, including the 
lungs, play a vital role in the induction of both innate and adaptive immunity. A need to 
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maintain local homeostasis, as well as, exposure to airborne antigens requires fine control 
of immunological processes (Holt et al., 1993).  Signals for the adaptive immune 
response come from a variety of stimuli in the lungs; allergens, environmental pollution, 
microorganisms within the respiratory tract, and innate immune cells must be processed 
as signals for the T cells (Lambrecht and Hammad, 2010).  “The large surface area, 
extensive vascularization and thin epithelium in the alveolar lung tissue might facilitate 
efficient systemic delivery of antigens (Sou et al., 2011).”  The action of DCs as well as 
intrinsic qualities of the lung tissue provides a prime target for in vivo immunotherapy.   
 
 
 
Figure 18. Diagram of the lung and particle-size requirements based on intended deposition region in the 
respiratory tract. Images on the right are magnified, cartoon views of tissue structures of the conducting 
airways (i.e. trachea, bronchi and bronchioles) and alveoli in the parenchyma region. Immunosuppressive 
alveolar macrophages and serum-derived antibodies provide a final line of protection against invading 
pathogens. A cellular and humoral immune response can be generated after interaction with innate immune 
receptors present on epithelial cells and tissue-resident DCs. (Sou et al., 2011) 
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  The development of a nanoparticle delivery system for cancer immunotherapy 
circumvents the need for isolation of the DCs from the patient, as well as, the adaptive 
transfer of pulsed DCs back into the patient.  Pulmonary delivery of nanoparticles has 
been shown to promote antigen uptake and trafficking to the draining LN by intrinsic 
DCs (Nembrini et al., 2011).  The delivery of tumor vaccines in form of an aerosol offers 
several advantages over the current distribution methods.  First, the technique does not 
require DC isolation.  Second, in vivo activation of endogenous DCs will bypass 
uncertainties associated with isolating DCs ex vivo, DC activation, and reimplantating of 
DCs.  Third, a future combination of aerosol delivery, targeted release of tumor antigens 
inside residential lung DCs, and imaging will allow for an unprecedented level of 
simplicity and reliability with the added benefit of a monitored response.  A study in 
2011 (Nembrini et al., 2011) found that when Pluronic-stabilized poly(propylene sulfide) 
(PPS) nanoparticles were delivered to the lungs, there was no visible change in lung 
morphology and no sign of permanent inflammation.  The study indicates that pulmonary 
administration of nanoparticles is not harmful to the lungs.  In this work, we attempt to 
validate delivery of aerosolized nanoparticles into the lungs of mice and track the 
migration of particle-laden DC’s into the draining LNs. 
 
Methods and Results 
 
Nasal Nebulization 
Nebulization of 30 nm SPIO nanoparticles conjugated to the epoxy amine linker 
was achieved using the Aeroneb Lab Micropump Nebulizer (Aerogen, Danagan, Ireland) 
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rated to produce an aerosol with particles of 2.5-4.0 µm mean diameter.  Two mice were 
nebulized in the provided mouse holding tube with 5 mL of SPIO nanoparticles twice at 
approximately a 3 hour interval.  The mice were sacrificed 24 hours post nebulization and 
the lungs isolated and frozen for histological staining.  The efficiency of SPIO 
nanoparticle delivery was confirmed with Prussian blue staining. 8 µm frozen sections of 
the harvested tissue were immobilized on a glass slide. The slides were dried at room 
temperature and fixed with 4% paraformaldehyde for 5 minutes. The samples were then 
stained with a freshly mixed 2.5% hydrochloric acid and 2.5% potassium ferrocyanide 
solution for 30 minutes. After washing with water, the slides were counterstained with 
0.1% nuclear fast red for 10 minutes. The slides were then visualized with light 
microscopy using a Zeiss Axioskip 40 microscope (Carl Zeiss MicroImaging, 
Thornwood, NY) equipped with AxioCam (Carl Zeiss MicroImaging, Thornwood, NY) 
for digital images with a 40 objective lens.  
 
 
 
Figure 19. Prussian blue staining of representative slides from two nebulized mice. 
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Figure 19 shows one representative slides from each of the mice that were 
nebulized with SPIO nanoparticles, although the nanoparticles can be detected in the 
lungs of these mice, the amount that is delivered is very small and improvements to 
nebulization techniques used in these mice are needed to more accurately mimic clinical 
nebulization.  
 
Nebulization through Intubation 
In order to improve the delivery of SPIO nanoparticles to the lungs of mice 
through nebulization, the nebulization was directed to the lungs through intubation, 
bypassing the instinct of the mouse to avoid inhaling the vapor.  Mice were anesthetized 
with an intraperitoneal injection of 0.06 mg/g ketamine and 0.01 mg/g xyalizine mixture. 
The animal was suspended from its front incisors. A 20 gauge Surflash polyurethane 
intravenous catheter and needle (Terumo, Somerset, NJ) were selected. The 20 gauge 
needle was discarded. A flexible fiber optic stylet was connected to a light source (Kent 
Scientific, Torrington, CT) and was attached to the catheter. Under direct visualization, 
the stylet-catheter system was placed through the larynx and into the trachea of the 
animal. The stylet was subsequently removed. Placement of the endotracheal tube was 
verified by occluding the tube with a drop of water and observing for movement with 
animal respiration. After confirming correct placement, the drop of water was removed 
and the endotracheal tube was connected to the ventilator and nebulizer in the 
configuration depicted in Figure 20, the mouse was placed on a heating pad while under 
anesthesia during nebulization. 
 
43 
 
 
 
Figure 20. A scematic of the nebulization through intubation system used is shown on the left next to a 
picture of the system in use on the right. 
 
 
The mouse was ventilated with a Topo Dual Mode Ventilator (Kent Scientific, 
Torrington, CT) supplying 120-150 breaths per minute, a peak inspiratory pressure 
between 10-15 cm H20, and an airflow of approximately 3 L per minute, using an 
Aeroneb Lab Micropump Nebulizer (Aerogen, Danagan, Ireland).  Five 1 mL aliquots of 
SPIO nanoparticles were passed through the nebulizer and delivered into the endotracheal 
tube. During ventilation and nebulization, the mouse was also monitored for signs of 
respiratory distress, such as abdominal contractions, which indicated that the animal was 
breathing against the ventilator. If distress was identified, ventilation and nebulization 
were paused, and the mouse was immediately extubated. After the distress resolved, the 
mouse was reintubated, ventilated and supplied with nebulized SPIO nanoparticles as 
above. The level of anesthesia was also monitored by testing the palpebral reflex and 
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response to tail pinch. Additional anesthesia was administered as needed to maintain the 
appropriate anesthetic plane. 
After successfully nebulizing 5 mL of SPIO nanoparticles, the mouse was 
disconnected from the ventilator and extubated. Recovery from anesthesia was monitored 
by testing the righting reflex. The animal was sacrificed 24 hours after nebulization. The 
trachea, lungs, and mediastinal LNs were harvested, embedded in optimal cutting 
temperature compound, and frozen for subsequent histology.   
Prussian blue staining to confirm the presence of SPIO nanoparticles was done as 
previously described in both the lung and LN tissue.  Consecutive slides were stained for 
DCs with immunohistochemistry.  The 8 µm frozen sections of the harvested tissue were 
immobilized on a glass slide were dried at room temperature, rehydrated with 0.1 % 
tween 20 in PBS, and treated with hydrogen peroxide to neutralize any endogenous 
peroxidases. The samples were then treated with bovine serum albumin (BSA) (Lab 
Vision, Fremont, CA) to block any nonspecific staining prior to primary antibody 
addition. After incubating the slides for 120 minutes with affinity-purified hamster anti-
CD11c antibody (eBioscience, San Diego, CA) diluted 1:200 in BSA, the slides were 
rinsed and incubated for 1 hour with purified goat anti-hamster antibody conjugated to 
biotin (eBioscience, San Diego, CA) diluted 1:1000 in BSA. The slides were 
subsequently washed and treated with the Vectastain ABC Elite system (Vector 
Laboratories, Burlingame, CA) and 3,30-diaminobenzidine (Dako, Carpinteria, CA) to 
produce localized, visible staining. Finally, the slides were counterstained with Meyer’s 
Hematoxylin (Sigma-Aldrich, St. Louis, MO). All sections were visualized with light 
microscopy as previously described. 
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Figure 21. Prussian blue iron staining in the lung tissue (A) and LN (C) 24 hours after nebulization.  CD11c 
immunohistochemistry for DCs of consecutive slides in the lungs (B) and LN (D). 
 
 
Confirmation of the delivery of the SPIO nanoparticles to the lungs can be seen in 
Figure 21.  The increase concentration of the iron compared to the previous study 
indicates the increased efficiency of nebulization using intubation over the nebulization 
alone.  Consecutive slides stained with CD11c show the area rich in DCs.  Co-
localization of the SPIO nanoparticles and DCs in consecutive slides proves promising 
toward the goal of cellular uptake by the DC of our delivery molecule.  Prussian blue 
staining within the mediastinal LN is positive for the presence of SPIO nanoparticles 
supporting our hypothesis of DC migration from the lungs to LN after uptake of the 
nanoparticles.   
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Nebulization with Hybrid Imaging Nanoprobe 
The same nebulization techniques were used in a study using fluorescent 
magnetic hybrid imaging nanoprobe (HINP).  The probe was a conjugation of SPIO and 
visible light emitting fluorescent CdTe/CdS quantum dots (QDs) developed by D. 
Koktysh (Koktysh et al., 2011).  The multimodal imaging agent combines an ability to be 
visualized by magnetic resonance (MR) imaging and through optical imaging.  This 
opportunity for optical imaging was used to verify the data obtained from the previous 
nebulization experiment.  The nebulization was performed as previously described after 
sedation with intubation.  In this experiment 10 mg/mL samples of HINP were diluted to 
4 mL in PBS.  The mouse received 2 mL of this solution through nebulization.  Imaging 
of the distribution through the whole mouse was not possible due to the thick and 
pigmented skin of the black mouse (C57BL/6). After approximately 5 hours the mouse 
was sacrificed and the lung and mediastinal LN were isolated for ex vivo imaging shown 
in Figure 22.  
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Figure 22. White light (A) and fluorescent (B) images of muscle tissue (I) compared to a dissected draining 
LN (II) of a mouse 24 hours post treatment. (Koktysh et al., 2011) 
 
 
The HINPs were able to be visualized in the lungs (data not shown) and in the 
mediastinal LN (Figure 22).  The results showing migration of the nanoparticles to the 
draining LN is promising for the future of immunotherapy using SPIO nanoparticles as a 
delivery vehicle to the endogenous DCs of the lungs.   
 
Future Work 
Due to problems with safety of intubated mice and inconsistencies between mice, 
in the future the work will move to use a new nebulization system seen in Figure 23.  
This custom designed nebulization system has advantages over previous systems.  The 
system allows for nebulization of three mice simultaneously, providing consistency 
across multiple mice (Figure 24).  The system includes an automated plunger which 
provides a constant flow of an inhalable amount of aerosol as opposed to nebulizing with 
multiple aliquots.  Nebulization occurs through a Jet nebulizer which works by passing 
the liquid to be aerosolized across a high pressured stream of air.  Unlike the mircopump 
48 
 
nebulizer this allows for constant production of aerosol at a slower, manageable rate.  The 
excess solution, that which is not aerosolized after passing through the stream of air, can 
be collected and quantified to determine experimental dose.   
 
 
 
Figure 23. Nebulization system in which three mice may be nebulized simultaneously, therefore in more 
closely related conditions. 
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Figure 24. Diagram of multi animal nebulization system indicating the route the aerosol takes during 
delivery to mice.   
 
 
With verification of the advantages of the new nebulization system over previous 
nebulization techniques and the completion of a well-defined antigen/adjuvant 
conjugated SPIO nanoparticle, progress can be made toward utilizing the information of 
nebulization to properly deliver immune activating molecules to the resident DCs in the 
lungs.  This delivery can then be compared to delivery through injection and pulsed-DC 
through cytokine concentration studies and tumor response studies.  Comparable 
treatment response with nebulization to other more difficult techniques will verify the use 
of aerosol delivery for immunotherapy and provide a simplified route of vaccinating 
against cancer.   
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CHAPTER IV 
 
Near Infrared Dye 
 
Rationale 
 Optical imaging is a powerful tool for non-invasive mapping of molecular events.  
Unlike other imaging modalities, optical imaging does not require contact with any 
iodizing radiation and is cost efficient.  Optical imaging involves detection of 
electromagnetic waves within the visible, infrared, and ultraviolet wavelengths.  
Emission of these wavelengths from the studied source can be produced in two ways, 
fluorescence and bioluminescence.  Bioluminescence is release of light due to chemical 
reactions occurring intrinsically in an organism.  This may be added to cells through 
transfection of bioluminescent genes.  Fluorescence occurs when a chromophore absorbs 
light and is excited to a higher energy level.  The molecule then relaxes and omits 
fluorescent light.  Fluorescent molecules have been conjugated to certain molecules in 
order to target a specific molecule or process in vivo.  A variety of targeting molecules 
can be used for a multitude of purposes including small-molecules looking at the folate 
receptor, peptides to image fibrin, proteins to study angiogenesis, and antibodies for the 
HER2/neu marker of cancer to name a few (Hilderbrand and Weissleder, 2010).  An ideal 
fluorescent dye for labeling of biomolecules must be water-soluble and chemically stable; 
it should have a large fluorescence quantum yield.  Inclusion of a reactive functional 
group which is stable in storage but has specific, highly efficient labeling to the targeting 
molecule producing a stable covalent bond is also important (Flanagan et al., 1997).   
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 NIR dyes are of particular interest in optical imaging due to the low in vivo 
absorbance in these wavelengths.  Biological chromophores are strong absorbers of 
visible light whereas other biomolecules absorb in the infrared.  The optimal imaging 
window is between 600 and 1000 nm, NIR (Hilderbrand and Weissleder, 2010).  Limited 
absorbance in this range allows for imaging to a depth of a few cm rather than the 1-2 
mm limit of visible wavelength fluorophores (Ntziachristos et al., 2003).  As wavelength 
increases, scattering and autofluorescence decrease lowering the background and 
therefore greater contrast (Pham et al., 2008).  NIR emitting molecules are either small 
molecule dyes or nanoparticles. Nanoparticle distribution is favorable due to its longer 
blood half-life, but small molecule dyes are powerful due to the ability to design 
molecules with large Stokes shift (the distance between absorbance and emission peaks) 
(Hilderbrand and Weissleder, 2010).  Two families of fluorescent dyes are cyanines and 
rhodamines.  Cyanines basic structure is a conjugated methionine bridge connecting two 
nitrogen-containing heterocyclic rings (Nolting et al, 2012).  Absorption and emission of 
cyanine dyes are dependent on their structure and can be designed based on known 
parameters.  The length of the polymethine chain and the identity of the heterocyclic 
rings effects on the overall absorption and emission wavelengths have been well 
characterized and can be tuned to the NIR region while keeping a compact structure 
compared to other dyes (Pham et al., 2005).  Rhodamine dyes are identified by 
conjugated hexagonal heterocycle backbone based off a xanthylium.  They usually 
contain a site that can be used for bioconjugation and are therefore popular for labeling of 
biomolecules (Nolting et al, 2012).   
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  IR-783 (see Figure 25) is a commercially available cyanine dye with absorbance 
and emission in the NIR range.  The 7-carbon length methionine bridge between indole 
rings determines the absorbance of this dye, with maximum between 779 and 785 nm.  
This stable dye is water soluble due to the addition of sulfonic acids.  The methionine 
bridge is stabilized by incorporation of the center three carbons into a 6-member ring.   
 
  
 
Figure 25. Structure of commercial NIR dye, IR-783  
 
 
 The commercial dye is ideal for optical imaging due its stability, water solubility, 
and NIR absorbance and emission, but lacks a site for bioconjugation.  Through chemical 
modification at the halide group a bioconjugation site can be added without interrupting 
the other necessary characteristics of this NIR dye for targeted imaging.   
 
Methods and Results 
 
Functionalization of Dye 
 The commercial dye, IR-783, is limited in its use as an optical probe by the 
absence of a site for bioconjugation to targeting molecules.  Pham et al. describes a 
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reaction whereby a halide containing cyanine dye can be modified to contain a carboxylic 
functional group (Pham et al., 2008).  The nucleophilic substitution by aminoundecanoic 
acid of the Cl improves the dye as a targeted optical probe in two ways: the inclusion of 
the carboxylic acid bioconjugation site and an increase of stokes shift from 30 nm to 140 
nm.  The same reaction can be applied to IR-783 in order to prime the molecule for 
labeling activation, generating a product that can readily be modified to a reactive 
compound, such as a succinimidyl ester. 
 Synthesis, as seen in Figure 26, was performed as follows: IR-783 (50.4 mg, 67.3 
mmol), 11-aminoundecanoic acid (17.9 mg, 88.9 mmol), and ethanol (EtOH) (4 mL) 
were added to a 2-5 mL microwave reaction vial (Biotage, Charlotte, NC). A stirbar was 
added and the vessel was sealed.  The solution was reacted in the microwave “Initiator” 
(Biotage, Charlotte, NC) for 1 hour at 100 °C with 30 seconds pre-stirring.  The product 
was verified by the appearance of a blue spot on TLC done in 2.5/7.5 MeOH/ 
dichloromethane (DCM).  The solution was loaded on a silica gel column for use on 
CombiFlash (Teledyne ISCO, Lincoln, NE) and purified using a 40 g column.  The 
fractions corresponding to the blue TLC spot were collected and dried.  The blue solid 
intermediate (B) was formed (32.4 mg, 65% yield).   
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Figure 26. Scheme for functionalization of NIR dye. 
 
 
 The reaction was monitored by a color change in the reaction solution, 
specifically from green to blue.  Absorbance and emissions spectra of the starting 
material (IR-783) was compared to the new blue intermediate, obtained from UV-vis 
Spectrophotometer (Agilent Technologies, Santa Clara, CA) and Fluorimeter (Photon 
Technology International, Birmingham, NJ)  The resulting excitation/emission peaks are 
graphed in Figure 27.  
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Figure 27. Absorbance and emission spectra from IR-783 and the blue intermediate normalized to maxima. 
 
 
 The addition of 11-aminoundecanoic acid in place of the Cl atom shifts the 
excitation maximum from 780 nm to 610 nm.  The shift of emission maximum is small 
from 810 nm to 750 nm.  An increase of Stokes shift from 30 nm to 140 nm widens the 
number of applications this dye may be used for, especially making the new dye ideal for 
such application as FRET.   
 
 Activation for Biomolecule Conjugation 
 There are a variety of molecules which can be used to activate a dye for 
bioconjugation; one of these is addition of a succinimidyl ester moiety (Flanagan et al., 
1997).  Succinimidyl ester is ideal because of it specific reactivity to primary amines 
present, including peptides and proteins, to form a stable peptide bond (Banks and 
Paquette, 1995).   
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 The second step of activating the NIR dye is as follows (Figure 28): the dye 
intermediate (B) (32.4 mg, 35.4 mmol), N,N'-dicyclohexylcarbodiimide (DCC) (12.6 mg, 
61.1 mmol), and NHS (12.9 mg, 112.1 mmol) were added to a dry 10 mL round bottom 
flask.  The flask was then purged with nitrogen and placed in a 0 °C ice bath.  DMF (2 
mL) was added to the flask to dissolve the solids.  The reaction vessel was allowed to 
warm to room temperature for 5 days until a precipitate, dicyclourea byproduct, was 
formed.  The solution was filtered and the filtrate was collected.  A TLC was done in 
2.5/7.5 MeOH/DCM showing separation of product from intermediate (B).  The solution 
was loaded on a silica gel column for use on CombiFlash (Teledyne ISCO, Lincoln, NE) 
and purified using a 40 g column.  The fractions corresponding to the product TLC spot 
were collected and dried.  A portion of dry product was sent to Mass Spectrometry Core 
for analysis by Time of Flight (TOF) Mass Spectrometry (MS) (Figure 29).   
 
 
 
Figure 28. Scheme for activation of NIR dye. 
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Figure 29. MS data shows the presence of the activated NIR dye product (m/z 987.4675) with a small 
amount of starting material (m/z 696.3377) and intermediate (B) (m/z 890.4507) impurities. 
 
 
MS indicates that the bioconjugation activated NIR dye was produced, with small 
amounts of precursor impurity.  The excitation and emission spectra of the final product 
was determined as previously described.   
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Figure 30. Excitation and emission of succinimidyl ester activated NIR dye product. 
 
 
 Figure 30 show the succinimidyl ester activated NIR dye retains the fluorescent 
properties of the reaction intermediate that are seen in Figure 27.  This includes a large 
Stokes shift of approximately 150 nm.   
 
Labeling Study 
To validate the bioconjugation ability of the succinimidyl ester NIR dye product a 
protein of interest was chosen.  Peanut agglutinin (PNA) is a protein which has been used 
to target imaging probes, both optical and radiolabeled, for mammary cancer cells (Seitz 
et al., 1984); (Shysh et al., 1985).  PNA is known for its high affinity binding to the 
Thomsen-Friedenreich antigen (TF-antigen).  TF-antigen is a known marker for 
adenocarcinoma cells of the breast (Seitz et al., 1984).  Labeling of this protein for optical 
imaging will allow increased observance of the tumor cells during therapy, increasing the 
ability to characterize the action of the SPIO nanovaccine.   
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 Biotinylated PNA (5 mg) and activated NIR dye (1.1 mg) was placed in a 10 mL 
round bottom flask.  PBS (1.5 mL, pH 7.49) was added and the solids dissolved.  The 
reaction was left under nitrogen for 4 hours.  The product was purified with a PD-10 
desalting column (GE Healthcare, Pittsburgh, PA) according to the manufacturer’s 
instructions with PBS.  The first blue band to pass through the column was collected.  
Absorbance spectra were determined with UV-vis Spectrophotometer (Agilent 
Technologies, Santa Clara, CA) of NIR dye before addition of the PNA and after the 
reaction.  The appearance of a peak between 260 and 280 nm (from the reaction 
byproduct, NHS) indicates success of the reaction (Figure 31).  To confirm the 
absorbance was due to NHS, the absorbance was measured again after passing through 
the desalting column.    
 
 
Figure 31. Absorbance of activation reagents and product normalized to dye peak.  Increase in absorbance 
between 260-280 nm indicates formation of the byproduct, not seen after purification. 
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Future Work 
 The PNA targeted NIR dye can be used in the future to visualize the breast cancer 
tumors in the in vivo studies of treatment response, providing another means of gaining 
information about the efficacy of the nanovaccine.  The shape and size of the tumor can 
be more accurately measured using optical imaging and the PNA conjugated NIR dye.   
The labeling of PNA shows that the modified commercial dye, IR-783, is a 
powerful tool for optical imaging in the NIR region.  The addition of the functional group 
and activation with a succinimidyl ester is a relatively simple synthesis that can be readily 
repeated.  Addition of the succinimidyl ester allows for bioconjugation to a number of 
biomolecules.  Further work can be done with this dye in a variety of studies through 
conjugation to any number of targeting molecules containing an amino group.    
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CHAPTER V 
 
Discussion 
 
 This thesis describes our work in immunotherapy, the use of SPIO nanoparticles 
as delivery molecules and for imaging, and our synthesis of a bioconjugatable NIR dye.  
The continued prevalence of cancer validates the need for the work we are doing in 
cancer therapy and imaging. Specifically, the discovery of DCs and the development of 
DC-based immunotherapy show promise as an approach to treating cancer.  Pre-clinical 
and clinical model studies have demonstrated the efficacy of immunotherapy despite the 
fact that this method is not without problems (Flamand et al., 1994; Grabbe et al., 1991, 
Mayordomo et al., 1995; Porgador et al., 1996; Hsu et al., 1996; Thurner et al., 1999; 
Fong et al., 2001; Lodge et al., 2000; Nair et al., 2002; Sadanaga et al., 2001; Brossart et 
al., 2000; Holtl et al., 1999; Kugler et al., 2000). Nevertheless, advances can be made in 
this area of research in order to achieve ultimately favorable outcomes for cancer 
patients. The chemical probes discussed in this thesis can be classified as molecular 
imaging probes.  The development of such probes for molecular imaging is a vital new 
element not only in cancer detection, but also in monitoring biological processes, drug 
discovery and development initiatives.   
 The use of SPIO nanoparticles as delivery molecules enables the conjugation of 
multiple molecules to the same nanovaccine as well as increase uptake in DCs compared 
to small antigen peptides alone (Hirosue et al., 2010).  The use of MUC1 for 
immunotherapy has been well defined and therefore represents an ideal antigen with 
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which to test a new therapy technique (Kobukai et al., 2011).  In that process, difficulties 
were experienced in the anime coupling to SPIO nanoparticles as well as the conjugation 
to biomolecules.  The epoxy amine linker was developed from sensitive chemistry to 
ensure the ready availability of epoxide for nanoparticle coupling.  Thus, the process 
requires highly skilled chemists to perform the task.  Unfortunately, the absence of a 
simple procedure with which to verify epoxy amine coupling to the SPIO nanoparticles 
adds to the uncertainty regarding the consistent production of aminated SPIO 
nanoparticles.  Attempts were made to circumvent this by producing a previously 
aminated CMDA dextran by following a published procedure.  The success of that 
molecule would be a landmark development since it would facilitate straightforward 
verification through ninhydrin staining, a technique that cannot be used on aminated 
nanoparticles due to its brown color.  While ninhydrin staining of the CMDA product 
indicated the presence of a primary amine, NMR results did not support that finding.  
Final FT-IR spectroscopy of the product indicated no amine frequency peak, and FT-IR 
data was supported by the inability to coat the SPIO nanoparticles. Ultimately, this 
synthesis approach was abandoned as a possible alternative to the epoxy amine linker.   
 Regarding the immunotherapy, we demonstrated as evidence that α-GalCer is a 
powerful adjuvant for activation of the innate immune system by modulating the 
production of IL-4 in Figure 10. The -GalCer works through a variety of pathways to 
activate the immune response. Importantly, the conjugation of α-GalCer to SPIO 
nanoparticles does not inhibit that function.   
 Conjugation of MUC1 and α-GalCer to SPIO nanoparticles was accomplished 
using the same approach as α-GalCer alone; yet the results derived via this nanovaccine 
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disagree with those of α-GalCer alone. The concentration of conjugated biomolecules 
could be calculated by the release of the by-product pyridine-2-thione.  Conjugation to 
SPIO nanoparticles was limited for both biomolecules.  We observed 2.6% of the 
available MUC1 and 8.7% of the α-GalCer was conjugated to the SPIO nanoparticles.  
Modification of the procedure by increasing the incubation time of SPIO nanoparticles 
with SPDP failed to improve conjugation to SPIO nanoparticles.  The possibility exists 
that the absorbance of SPIO nanoparticles alone could mask the detection of pyridine-2-
thione at 343 nm, but therapy results and cytokine production support the conclusion that 
conjugation to the SPIO nanoparticles was not as successful as expected.  Another 
possible cause for the discrepancy between these results and the previous results with α-
GalCer alone is that the α-GalCer is a difficult molecule to produce and its limited 
solubility makes storage difficult.  Thus, the molecule may have degraded before it could 
be conjugated to the SPIO nanoparticles. The most likely contributor in these conjugation 
challenges is the amine surface of the nanoparticle.   
 Therapy using our nanovaccine on mice indicated inhibition of tumor growth yet 
not at a robust level.  Assessment of cytokine production after injection of the 
nanovaccine showed a complete absence of expected cytokines.  This means that 
injection of our nanovaccine was unable to activate the expected immune response.  This 
conclusion was supported by comparing cytokine expression with injection of the 
nanovaccine and soluble solutions.  The soluble solutions elicited an immune response 
unlike the nanoparticle bound, an observation supporting the conclusion that conjugation 
of the biomolecules to SPIO nanoparticles was unsuccessful.  While the therapy showed 
some promise in terms of tumor response, future therapy and cytokine measurements 
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should include additional positive and negative controls to facilitate a more robust 
interpretation of the results. Additionally, analytical chemistry and quality control must 
be utilized to ensure the presence of adjuvant and tumor antigen on the surface of the 
nanoparticles.  
 Nebulization has been identified as a means through which to accomplish the 
intrinsic presentation of antigenic molecules to DCs in the lungs. The first technique used 
for nebulization, through the nose of the animal, was mostly unsuccessful due to the 
imperfections of the nebulizing device. In many cases, the animal avoided breathing the 
aerosol since too much room was available within the containment chamber.  The 
intubation of the mice for nebulization was more successful in delivering nanoparticles to 
the lungs as can be seen in the histology data, as well as optical imaging with the HINP.  
Histology of SPIO nanoparticles in the LN, as well as, optical imaging of HINP showed 
presence of nebulized nanoparticles in the mediastinal LNs.  That data supports our 
hypothesis that lung DCs uptake the nebulized nanoparticles and migrate to the LN with 
the intracellular nanoparticles.  The increased success of nebulization with the intubation 
technique was not without its drawbacks.  The intubation process was found to be 
dangerous to the animal and the concentration of SPIO nanoparticles that was delivered 
to the lungs was not consistent across animals.  Therefore, a new nebulizer was designed 
to simplify nebulization compared to the technique using intubation while keeping its 
advantage over the initial nebulization system.   
 The development of a NIR dye that can be conjugated onto biomolecules is 
desirable, especially as a molecular probe capable of being targeted to a certain place or 
process in vivo.  NIR wavelengths are optimal for optical imaging due the low 
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absorbance and scattering of these wavelengths in tissue, which allows such dyes to be 
imaged up to a 1-2 centimeters into tissues.  A commercial NIR dye was used for this 
study to focus on the activation of the dye rather than the synthesis of a new cyanine dye.  
It is worth mentioning that this synthesis was reported from the Pham Laboratory (Pham 
et al., 2008).  The purpose of this work is to fine tune the chemistry for improving the 
dye’s stability.  The functionalization of the dye with aminoundecanoic acid to provide 
activation site in the carboxylic acid proceeds through an SN2 nucleophilic substitution.  
Interestingly, this reaction produced a better yield in EtOH than DMF despite being a 
polar protic solvent.  The reaction was carried out with relative ease due to microwave 
synthesis and purified with CombiFlash chromatography.  The yield of this reaction was 
approximately 65%.  The carboxylic acid can be activated with DCC and NHS to form a 
succinimidyl ester.  This reaction proceeds in an oxygen-free environment and is 
monitored by the production of a precipitate byproduct.  After filtering away the 
byproduct, the product can be purified with CombiFlash chromatography.  
Bioconjugation of the NIR dye to PNA provides preliminary evidence towards the 
utility of a succinimide-activated NIR dye for optical imaging.  Conjugation of the NIR 
dye is a simple process that can be easily repeated with a variety of targeting 
biomolecules.  
 The challenges and advances identified in these studies can be used for the future 
development of a nebulizing nanovaccine for cancer treatment. Given the robustness of 
optical imaging, a targetable NIR dye can help validate the use of such an approach.   
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